UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

xQuarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended JuneSeptember 30, 2013
or
or
oTransition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from    to

Commission File Number 0-10763

Atrion Corporation
(Exact Name of Registrant as Specified in its Charter)
Atrion Corporation
(Exact Name of Registrant as Specified in its Charter)
   
Delaware 63-0821819
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
   
One Allentown Parkway, Allen, Texas  75002
(Address of Principal Executive Offices) (Zip Code)
 
(972) 390-9800
(Registrant’s Telephone Number, Including Area Code)

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  x Yeso  No

Indicate by check whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “accelerated filer.” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):
 
Large accelerated filer oAccelerated filer xNon-accelerated filer oSmaller reporting company o
 
Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   o Yes   xNo

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

 
Title of Each Class
 
Number of Shares Outstanding at
July 15,October 14, 2013
Common stock, Par Value $0.10 per share 2,007,4792,002,704

 
 
 

 

ATRION CORPORATION AND SUBSIDIARIES


TABLE OF CONTENTS


2
 
 
 Item 1.Financial Statements
3
 
 June 30, 2013 and 20123
4
 
 5
 
 For the Six months Ended
June 30, 2013 and 20125
6
 
9
 
8
Item 3.
1314
 
1314
 
1314
 
1314
 
1314
 
14
Item 6.Exhibits14
SIGNATURES15
 
15
 
16
1617


 
1

 
 

 
 
 
PART I










FINANCIAL INFORMATION
 

 
 
2

 
 
Item 1.Financial1.Financial Statements

ATRION CORPORATION AND SUBSIDIARIES
 (Unaudited)

  
Three Months Ended
June 30,
  
Six Months Ended
June 30,
  2013 2012 2013 2012
  (In thousands, except per share amounts)
             
Revenues $32,605  $30,689  $66,097  $59,929 
Cost of goods sold  16,971   16,016   34,754   31,427 
Gross profit  15,634   14,673   31,343   28,502 
Operating expenses:                
Selling  1,481   1,465   3,066   2,907 
General and administrative  3,706   3,397   7,300   6,868 
Research and development  952   844   2,082   1,817 
   6,139   5,706   12,448   11,592 
Operating income  9,495   8,967   18,895   16,910 
                 
Interest income  346   359   695   649 
Other income, net  --   --   --   2 
   346   359   695   651 
                 
Income before provision for income taxes  9,841   9,326   19,590   17,561 
Provision for income taxes  (3,335)  (3,227)  (6,450)  (6,085)
                 
Net income $6,506  $6,099  $13,140  $11,476 
                 
Net income per basic share $3.23  $3.03  $6.51  $5.70 
Weighted average basic shares outstanding  2,015   2,016   2,017   2,015 
                 
                 
Net income per diluted share $3.22  $3.02  $6.50  $5.67 
Weighted average diluted shares outstanding  2,019   2,019   2,021   2,023 
                 
Dividends per common share $0.56  $0.49  $1.12  $0.98 
  
Three Months Ended
September 30,
  
Nine months Ended
September 30,
 
  2013  2012  2013  2012 
  (In thousands, except per share amounts) 
Revenues $34,044  $30,637  $100,142  $90,565 
Cost of goods sold  17,003   15,742   51,757   47,168 
Gross profit  17,041   14,895   48,385   43,397 
Operating expenses:                
Selling  1,530   1,301   4,596   4,208 
General and administrative  3,651   3,164   10,952   10,033 
Research and development  1,147   753   3,229   2,569 
   6,328   5,218   18,777   16,810 
Operating income  10,713   9,677   29,608   26,587 
                 
Interest income  310   411   1,005   1,060 
Other income, net  --   --   --   2 
   310   411   1,005   1,062 
                 
Income before provision for income taxes  11,023   10,088   30,613   27,649 
Provision for income taxes  (3,350)  (2,829)  (9,800)  (8,914)
                 
Net income $7,673  $7,259  $20,813  $18,735 
                 
Net income per basic share $3.82  $3.60  $10.33  $9.30 
Weighted average basic shares outstanding  2,007   2,014   2,014   2,015 
                 
                 
Net income per diluted share $3.81  $3.59  $10.31  $9.24 
Weighted average diluted shares outstanding  2,016   2,022   2,019   2,028 
                 
Dividends per common share $0.64  $0.56  $1.76  $1.54 
 
The accompanying notes are an integral part of these statements.
 
 
3

 
 
ATRION CORPORATION AND SUBSIDIARIES
(Unaudited)
 
  June 30, December 31, 
Assets 2013 2012
  (in thousands)
Current assets:      
Cash and cash equivalents $20,269  $7,999 
Short-term investments  12,574   8,182 
Accounts receivable  17,126   13,054 
Inventories  25,183   23,779 
Prepaid expenses and other current assets  2,300   3,110 
Deferred income taxes  623   623 
   78,075   56,747 
         
Long-term investments  20,124   28,433 
         
Property, plant and equipment  125,922   124,180 
Less accumulated depreciation and amortization  68,135   64,912 
   57,787   59,268 
Other assets and deferred charges:        
Patents  756   837 
Goodwill  9,730   9,730 
Other  869   795 
   11,355   11,362 
         
Total assets $167,341  $155,810 
         
Liabilities and Stockholders’ Equity        
Current liabilities:         
Accounts payable and accrued liabilities $9,627  $6,743 
Accrued income and other taxes  735   465 
   10,362   7,208 
         
Line of credit  --   -- 
         
Other non-current liabilities  13,331   13,774 
         
Stockholders’ equity:        
Common stock, par value $0.10 per share; authorized 10,000 shares, issued 3,420 shares  342   342 
Paid-in capital  30,822   29,998 
Retained earnings  163,502   152,630 
Treasury shares, 1,412 at June 30, 2013 and 1,399 at December 31, 2012, at cost  (51 ,018)  (48,142)
Total stockholders’ equity  143,648   134,828 
Total liabilities and stockholders’ equity $167,341  $155,810 
 
Assets
 
September 30,
2013
 
December 31,
2012
  (in thousands) 
Current assets:      
Cash and cash equivalents $30,724  $7,999 
Short-term investments  8,448   8,182 
Accounts receivable  16,183   13,054 
Inventories  26,488   23,779 
Prepaid expenses and other current assets  1,592   3,110 
Deferred income taxes  623   623 
   84,058   56,747 
         
Long-term investments  20,104   28,433 
         
Property, plant and equipment  127,851   124,180 
Less accumulated depreciation and amortization  70,163   64,912 
   57,688   59,268 
         
Other assets and deferred charges:        
Patents  716   837 
Goodwill  9,730   9,730 
     Other  812   795 
   11,258   11,362 
         
     Total assets $173,108  $155,810 
         
         
Liabilities and Stockholders’ Equity        
Current liabilities:        
Accounts payable and accrued liabilities $9,268  $6,743 
Accrued income and other taxes  1,636   465 
   10,904   7,208 
         
Line of credit  --   -- 
         
Other non-current liabilities  12,968   13,774 
         
Stockholders’ equity:        
 Common stock, par value $0.10 per share; authorized 10,000 shares, issued 3,420 shares  342   342 
Paid-in capital  31,203   29,998 
Retained earnings  169,883   152,630 
Treasury shares,1,417 at September 30, 2013 and 1,399 at December 31, 2012, at cost  (52,192)  (48,142)
Total stockholders’ equity
  149,236   134,828 
         
         
    Total liabilities and stockholders’ equity $173,108  $155,810 
 
The accompanying notes are an integral part of these financial statements.
 
 
4

 
 
ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
  Six Months Ended
  June 30,
  2013 2012
  (In thousands)
Cash flows from operating activities:      
Net income $13,140  $11,476 
Adjustments to reconcile net income to net cash provided by operating activities:        
Depreciation and amortization  4,271   3,562 
Deferred income taxes  (449)  315 
Stock-based compensation  842   729 
Net change in accrued interest, premiums, and discounts on investments
  278   368 
Other  26   -- 
   18,108   16,450 
         
Changes in operating assets and liabilities:        
Accounts receivable  (4,072)  (3,698)
Inventories  (1,404)  (317)
Prepaid expenses  810   95 
Other non-current assets  (73)  (81)
Accounts payable and accrued liabilities  2,884   (1,198)
Accrued income and other taxes  270   (369)
Other non-current liabilities  6   13 
   16,529   10,895 
         
Cash flows from investing activities:        
Property, plant and equipment additions  (2,735)  (5,580)
Purchase of investments  --   (21,545)
Proceeds from maturities of investments  3,639   6,750 
   904   (20,375)
         
Cash flows from financing activities:        
Shares tendered for employees’ withholding taxes on stock-based compensation  --   (1,065)
Issuance of treasury stock  --   153 
Tax benefit related to stock-based compensation  6   929 
Purchase of treasury stock  (2,912)  (4,756)
Dividends paid  (2,257)  (1,976)
   (5,163)  (6,715)
         
Net change in cash and cash equivalents  12,270   (16,195)
Cash and cash equivalents at beginning of period  7,999   24,590 
Cash and cash equivalents at end of period $20,269  $8,395 
         
         
         
Cash paid for:        
Income taxes $5,323  $4,567 
 
  
Nine months Ended
September 30,
  2013  2012 
       
Cash flows from operating activities:      
Net income $20,813  $18,735 
  Adjustments to reconcile net income to net cash provided by operating activities:        
Depreciation and amortization  6,388   5,563 
Deferred income taxes  (608)  1,097 
Stock-based compensation  1,215   1,106 
Net change in accrued interest, premiums, and discounts        
    on investments  424   556 
Other  26   -- 
   28,258   27,057 
         
Changes in operating assets and liabilities:        
Accounts receivable  (3,129)  (3,356)
Inventories  (2,709)  70 
Prepaid expenses  1,518   823 
Other non-current assets  (17)  (96)
Accounts payable and accrued liabilities  2,525   (543)
Accrued income and other taxes  1,172   135 
Other non-current liabilities  (198)  (723)
   27,420   23,367 
         
Cash flows from investing activities:        
Property, plant and equipment additions  (4,713)  (7,978)
Purchase of investments  --   (21,545)
Proceeds from maturities of investments  7,639   11,750 
   2,926   (17,773)
         
Cash flows from financing activities:        
Shares tendered for employees’ withholding taxes on stock-based compensation  --   (1,065)
Issuance of treasury stock  --   153 
Tax benefit related to stock-based compensation  6   929 
Purchase of treasury stock  (4,086)  (4,756)
Dividends paid  (3,541)  (3,104)
   (7,621)  (7,843)
         
Net change in cash and cash equivalents  22,725   (2,249)
Cash and cash equivalents at beginning of period  7,999   24,590 
Cash and cash equivalents at end of period $30,724  $22,341 
         
         
         
Cash paid for:        
Income taxes $7,927  $6,471 
The accompanying notes are an integral part of these financial statements.
 
 
5

 
 
ATRION CORPORATION AND SUBSIDIARIES
(Unaudited)
 
(1)           Basis of Presentation
 
The accompanying unaudited consolidated financial statements of Atrion Corporation and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, these statements include all adjustments necessary to present a fair statement of our consolidated results of operations, financial position and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the financial statements and notes. Actual results could differ from those estimates. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2012 ("2012 Form 10-K").  References herein to "Atrion," the "Company," "we," "our," and "us" refer to Atrion Corporation and its subsidiaries.

(2)           Inventories
Inventories are stated at the lower of cost or market. Cost is determined by using the first-in, first-out method. The following table details the major components of inventories (in thousands):
 
  September 30,  December 31, 
  2013  
2012
 
 Raw materials $11,081  $10,017 
 Work in process  6,877   5,268 
 Finished goods  8,530   8,494 
 Total inventories $26,488  $23,779 


  June 30, December 31,
  2013 
2012
Raw materials $11,299  $10,017 
Work in process  5,686   5,268 
Finished goods  8,198   8,494 
Total inventories $25,183  $23,779 
6

 
ATRION CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

(3)           Income per share
The following is the computation for basic and diluted income per share:

 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
Three Months Ended
September 30,
  
Nine months Ended
September 30,
 
 2013 2012 2013 2012 2013  2012  2013  2012 
 (in thousands, except per share amounts) (in thousands, except per share amounts) 
Net income $6,506  $6,099  $13,140  $11,476  $7,673  $7,259  $20,813  $18,735 
                                
Weighted average basic shares outstanding  2,015   2,016   2,017   2,015   2,007   2,014   2,014   2,015 
Add: Effect of dilutive securities  4   3   4   8   9   8   5   13 
Weighted average diluted shares outstanding  2,019   2,019   2,021   2,023   2,016   2,022   2,019   2,028 
 
Earnings per share:                        
Basic $3.23  $3.03  $6.51  $5.70  $3.82  $3.60  $10.33  $9.30 
Diluted $3.22  $3.02  $6.50  $5.67  $3.81  $3.59  $10.31  $9.24 
6

ATRION CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Incremental shares from stock options and restricted stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method. Dilutive securities representing 6,7111,545 and 6,5475,901 shares of common stock for the quarters ended JuneSeptember 30, 20122013 and 2013,2012, respectively, were excluded from the computation of weighted average diluted shares outstanding because their effect would have been anti-dilutive.

(4)           Investments
As of JuneSeptember 30, 2013, we held certain investments that are required to be measured for disclosure purposes at fair value on a recurring basis. These investments are considered Level 2 investments and are all considered to be held-to-maturity securities. We consider as current assets those investments which will mature in the next 12 months. The remaining investments are considered non-current assets. The amortized cost and fair value of our investments, and the related gross unrealized gains and losses, were as follows as of JuneSeptember 30, 2013 (in thousands):
    Gross Unrealized       Gross Unrealized    
 Cost Gains Losses Fair Value Cost  Gains  Losses  Fair Value 
Short-term Investments:                        
Corporate bonds $12,574  $188  $(4) $12,758  $8,448  $142  $--  $8,590 
                                
Long-term Investments                                
Corporate bonds $20,124  $349  $--  $20,473  $20,104  $426  $--  $20,530 

At JuneSeptember 30, 2013, the length of time until maturity of these securities ranged from half a month7.5 months to 22.518.5 months.
7

 
ATRION CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(5)Income Taxes
Our
The effective tax rate for the secondthird quarter of 2013 was 33.930.4 percent, compared with 34.628.0 percent for the secondthird quarter of 2012. OurThe effective tax rate for the first sixnine months of 2013 was 32.932.0 percent, compared with 34.732.2 percent for the first sixnine months of 2012. The decrease in our effective tax raterates for both the secondthird quarter and the first sixnine months of 2013 was primarily related to benefited from the extension of the federal research tax credit provisions included in the American Taxpayer Relief Act of 2012, which was signed into law on January 2, 2013. Additionally, retroactive benefitsThe effective tax rates for the third quarter and first nine months of 2012 benefited from a favorable adjustment to an uncertain tax incentivesposition related to income tax credits claimed for 2012 research and development expenditures were includedfollowing the conclusion, in September 2012, of an Internal Revenue Service examination of our United States federal income tax returns for 2006, 2007 and 2008. We expect the calculation of income taxeseffective tax rate for the first six monthsremainder of 2013.2013 to be approximately 34.0 percent.

(6)           Recent Accounting Pronouncements

From time to time, new accounting standards updates applicable to us are issued by the Financial Accounting Standards Board, or FASB, which we will adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards updates that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.

 
78

 

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We develop and manufacture products primarily for medical applications. We market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. Our medical products primarily serve the fluid delivery, cardiovascular, and ophthalmology markets. Our other medical and non-medical products include instrumentation and disposables used in dialysis andcategory includes valves and inflation devices used in marine and aviation safety products.
 
Our products are used in a wide variety of applications by numerous customers. We encounter competition in all of our markets and compete primarily on the basis of product quality, price, engineering, customer service and delivery time.
 
Our strategy is to provide a broad selection of products in the areas of our expertise. Research and development efforts are focused on improving current products and developing highly-engineered products that meet customer needs and have the potential for broad market applications and significant sales.in niche markets. Proposed new products may be subject to regulatory clearance or approval prior to commercialization and the time period for introducing a new product to the marketplace can be unpredictable. We also focus on controlling costs by investing in modern manufacturing technologies and controlling purchasing processes. We have been successful in consistently generating cash from operations and have used that cash to reduce indebtedness, to fund capital expenditures, to repurchase stock and to pay dividends.
 
Our strategic objective is to further enhance our position in our served markets by:
 
Focusing on customer needs;
Expanding existing product lines and developing new products;
Maintaining a culture of controlling cost; and
Preserving and fostering a collaborative, entrepreneurial management structure.working environment.
 
For the three months ended JuneSeptember 30, 2013, we reported revenues of $32.6$34.0 million, operating income of $9.5$10.7 million and net income of $6.5$7.7 million, up 611 percent, 611 percent and 76 percent, respectively, from the three months ended JuneSeptember 30, 2012. For the sixnine months ended JuneSeptember 30, 2013, we reported revenues of $66.1$100.1 million, operating income of $18.9$29.6 million and net income of $13.1$20.8 million, up 1011 percent, 1211 percent and 1511 percent, respectively, from the sixnine months ended JuneSeptember 30, 2012.

Results for the three months ended JuneSeptember 30, 2013

Consolidated net income totaled $6.5$7.7 million, or $3.23$3.82 per basic and $3.22$3.81 per diluted share, in the secondthird quarter of 2013. This is compared with consolidated net income of $6.1$7.3 million, or $3.03$3.60 per basic and $3.02$3.59 per diluted share, in the secondthird quarter of 2012. The income per basic share computations are based on weighted average basic shares outstanding of 2,015,0002,007,000 in the 2013 period and 2,016,0002,014,000 in the 2012 period.
8

The income per diluted share computations are based on weighted average diluted shares outstanding of 2,019,0002,016,000 in both the 2013 and 2,022,000 in the 2012 period.
 
9

Consolidated revenues of $32.6$34.0 million for the secondthird quarter of 2013 were 611 percent higher than revenues of $30.7$30.6 million for the secondthird quarter of 2012. This increase was primarily attributable to higher sales volumes.

Revenues by product line were as follows (in thousands):

 
Three Months ended
June 30,
 
Three Months ended
September 30,
 
 2013 2012 2013  2012 
            
Fluid Delivery $13,036  $13,394  $13,411  $13,160 
Cardiovascular  10,143   9,515   10,429   8,481 
Ophthalmology  5,016   3,653   5,127   3,934 
Other  4,410   4,127   5,077   5,062 
Total
 $32,605  $30,689  $34,044  $30,637 


Cost of goods sold of $17.0 million for the secondthird quarter of 2013 was $955,000$1.3 million higher than in the comparable 2012 period. Our cost of goods sold in the secondthird quarter of 2013 was 52.149.9 percent of revenues compared with 52.251.4 percent of revenues in the secondthird quarter of 2012.

Gross profit of $15.6$17.0 million in the secondthird quarter of 2013 was $961,000,$2.1 million, or 714 percent, higher than in the comparable 2012 period. Our gross profit percentage in the secondthird quarter of 2013 was 47.950.1 percent of revenues compared with 47.848.6 percent of revenues in the secondthird quarter of 2012. The increase in gross profit percentage in the 2013 period compared to the 2012 period was primarily relatedprincipally attributable to a favorable product sales mix, improved manufacturing capacity utilization, and the impact of continued cost improvement initiatives partially offset by increased compensation, manufacturing supplies and depreciation.

Our secondthird quarter 2013 operating expenses of $6.1$6.3 million were $433,000$1.1 million higher than the operating expenses for the secondthird quarter of 2012. This increase was comprised of a $108,000$394,000 increase in Research and Development, or R&D, expenses, a $16,000$229,000 increase in Selling expenses and a $309,000$487,000 increase in General and Administrative, or G&A, expenses. The increase in R&D costs was primarily relatedprincipally attributable to increased supplies, outside services and compensation. The increase in Selling expenses for the secondthird quarter of 2013 was primarily relatedprincipally attributable to increased outside services partially offset by reducedpromotion and advertising, increased commissions compensation and other miscellaneousincreased travel-related expenses. The increase in G&A expenses for the secondthird quarter of 2013 was principally attributable to increased compensation and outside services.

Operating income in the secondthird quarter of 2013 increased $528,000$1.0 million to $9.5$10.7 million, a 6an 11 percent increase from our operating income in the quarter ended JuneSeptember 30, 2012. Operating income was 2931 percent of revenues in both the secondthird quarter of 2013 and 32 percent in the secondthird quarter of 2012. The primary contributor to the increase in operating income for the third quarter of 2013 was the previously mentioned increase in revenues.

10


Income tax expense for the secondthird quarter of 2013 was $3.3$3.4 million compared to income tax expense of $3.2$2.8 million for the same period in the prior year. The effective tax rate for the secondthird quarter of 2013 was 33.930.4 percent, compared with 34.628.0 percent for the secondthird quarter of 2012. The lower secondthird quarter 2013 effective rate benefited from the extension of the federal research tax credit provisions included in the American Taxpayer Relief Act of 2012, which was signed into law on January 2, 2013. The lower effective tax rate for the third quarter of 2012 was principally attributable to a favorable adjustment to an uncertain tax position related to income tax credits claimed for R&D following the conclusion, in September 2012, of an Internal Revenue Service examination of our United States federal income tax returns for 2006, 2007 and 2008. We expect the effective tax rate for the remainder of 2013 to be approximately 34.0 percent.
9


Results for the sixnine months ended JuneSeptember 30, 2013

Consolidated net income totaled $13.1$20.8 million, or $6.51$10.33 per basic and $6.50$10.31 per diluted share, in the first sixnine months of 2013. This is compared with consolidated net income of $11.5$18.7 million, or $5.70$9.30 per basic and $5.67$9.24 per diluted share, in the first sixnine months of 2012. The income per basic share computations are based on weighted average basic shares outstanding of 2,017,0002,014,000 in the 2013 period and 2,015,000 in the 2012 period. The income per diluted share computations are based on weighted average diluted shares outstanding of 2,021,0002,019,000 in the 2013 period and 2,023,0002,028,000 in the 2012 period.

Consolidated revenues of $66.1$100.1 million for the first sixnine months of 2013 were 1011 percent higher than revenues of $59.9$90.6 million for the first sixnine months of 2012. This increase was primarily attributable to higher sales volumes.

Revenues by product line were as follows (in thousands):

  
Nine months ended
September 30,
 
  2013  2012 
       
Fluid Delivery $39,159  $37,934 
Cardiovascular  30,723   27,306 
Ophthalmology  15,939   11,245 
Other  14,321   14,080 
Total
 $100,142  $90,565 
  
Six Months ended
June 30,
  2013 2012
       
Fluid Delivery $25,748  $24,774 
Cardiovascular  20,294   18,825 
Ophthalmology  10,811   7,311 
Other  9,244   9,019 
Total
 $66,097  $59,929 


Cost of goods sold of $34.8$51.8 million for the first sixnine months of 2013 was $3.3$4.6 million higher than in the comparable 2012 period. Our cost of goods sold in the first sixnine months of 2013 was 52.651.7 percent of revenues compared with 52.452.1 percent of revenues in the first sixnine months of 2012.

Gross profit of $31.3$48.4 million in the first sixnine months of 2013 was $2.8$5.0 million, or 1011 percent, higher than in the comparable 2012 period. Our gross profit percentage in the first sixnine months of 2013 was 47.448.3 percent of revenues compared with 47.647.9 percent of revenues in the first sixnine months of 2012. The decreaseincrease in gross profit percentage in the 2013 period compared to the 2012 period was primarily relatedprincipally attributable to increased depreciation,a favorable product sales mix, improved manufacturing capacity utilization, and the impact of continued cost improvement initiatives partially offset by increased compensation and lower manufacturing efficiencies partially offset by a favorable product mix and continued cost improvements.depreciation.

11

Our first sixnine months 2013 operating expenses of $12.5$18.8 million were $856,000$2.0 million higher than the operating expenses for the first sixnine months of 2012. This increase was comprised of a $265,000$660,000 increase in R&D expenses, a $159,000$388,000 increase in Selling expenses and a $432,000$919,000 increase in G&A expenses. The increase in R&D costs was primarily relatedprincipally attributable to increased outside services, compensation, supplies and depreciation.
10

travel-related expenses. The increase in Selling expenses for the first sixnine months of 2013 was primarily relatedprincipally attributable to increased compensation, travel, promotion, advertising and outside services partially offset by reduced commissions, promotion and advertising.services. The increase in G&A expenses for the first sixnine months of 2013 was principally attributable to increased compensation partially offset by reducedand outside services.

Operating income in the first sixnine months of 2013 increased $2.0$3.0 million to $18.9$29.6 million, a 12an 11 percent increase from our operating income in the sixnine months ended JuneSeptember 30, 2012. Operating income was 30 percent of revenues in the first nine months of 2013 compared to 29 percent of revenues in the first six months of 2013 compared to 28 percent of revenues in the first sixnine months of 2012. The majorprimary contributor to the increase in operating income for the first sixnine months of 2013 was the previously mentioned increase in revenues.

Income tax expense for the first sixnine months of 2013 was $6.5$9.8 million compared to income tax expense of $6.1$8.9 million for the same period in the prior year. The effective tax rate for the first sixnine months of 2013 was 32.932.0 percent, compared with 34.732.2 percent for the first sixnine months of 2012. The lower first six months 2013 effective rate benefited from the retroactive extension of the federal research tax credit provisions included in the American Taxpayer Relief Act of 2012, which was signed into law on January 2, 2013. Benefits from tax incentives for 2012 research and development expenditures were included in the calculation of income taxes for the first six months of 2013. We expect theThe effective tax rate for the remainder2012 period benefited from a favorable adjustment to an uncertain tax position related to income tax credits claimed for R&D following the conclusion, in September 2012, of 2013 to be approximately 34.0 percent.an Internal Revenue Service examination of our United States federal income tax returns for 2006, 2007 and 2008.

Liquidity and Capital Resources
We have a $40.0 million revolving credit facility with a money center bank that can be utilized for the funding of operations and for major capital projects or acquisitions, subject to certain limitations and restrictions. Borrowings under the credit facility bear interest that is payable monthly at 30-day, 60-day or 90-day LIBOR, as selected by us, plus one percent. From time to time prior to October 1, 2016 and assuming an event of default is not then existing, we can convert outstanding advances under the revolving line of credit to term loans with a term of up to two years. We had no outstanding borrowings under our credit facility at JuneSeptember 30, 2013 or at December 31, 2012. The credit facility contains various restrictive covenants, none of which is expected to impact our liquidity or capital resources. At JuneSeptember 30, 2013, we were in compliance with all financial covenants. We believe that the bank providing the credit facility is highly-rated and that the entire $40.0 million under the credit facility is currently available to us. If that bank were unable to provide such funds, we believe that such inability would not impact our ability to fund operations.

At JuneSeptember 30, 2013, we had a total of $53.0$59.3 million in cash and cash equivalents, short-term investments and long-term investments, an increase of $8.4$14.7 million from December 31, 2012, which was principally attributable to increased operational results.

12

Cash flows from operating activities generated $16.5$27.4 million for the sixnine months ended JuneSeptember 30, 2013 as compared to $10.9$23.4 million for the sixnine months ended JuneSeptember 30, 2012. The increase in the 2013 period was primarily attributable to increasedimproved operational results as compared to the 2012 period and decreased cash requirements for working capital items, specifically accounts payable and accrued liabilities for the 2013 period. During the first sixnine months of 2013, we expended $2.7$4.7 million for the addition of property and equipment, $2.9$4.1 million for treasury stock and $2.3$3.5 million for dividends. During that same period, maturities of investments generated $3.6$7.6 million.

11

At JuneSeptember 30, 2013, we had working capital of $67.7$73.2 million, including $20.3$30.7 million in cash and cash equivalents and $12.6$8.5 million in short-term investments. The $18.2$23.6 million increase in working capital during the first sixnine months of 2013 was primarily relatedprincipally attributable to increases in cash and cash equivalents, short-term investments, accounts receivable and inventories partially offset by increases in accounts payable and accrued liabilities. The net increase in cash and short-term investmentscash equivalents was primarily relatedprincipally attributable to increases in accounts payable and accrued liabilities, increases in accrued income and other taxes, decreases in long-term investments.investments and improved operational results.

We believe that our $53.0$59.3 million in cash, cash equivalents, short-term investments and long-term investments, along with cash flows from operations and available borrowings of up to $40.0 million under our credit facility will be sufficient to fund our cash requirements for at least the foreseeable future. We believe that our strong financial position would allow us to access equity or debt financing should that be necessary. Additionally, we believe that our cash and cash equivalents, short-term investments and long-term investments, as a whole, will continue to increase during the remainder of 2013.

Forward-Looking Statements
Statements in this Management’s Discussion and Analysis and elsewhere in this Quarterly Report on Form 10-Q that are forward looking are based upon current expectations, and actual results or future events may differ materially. Therefore, the inclusion of such forward-looking information should not be regarded as a representation by us that our objectives or plans will be achieved. Such statements include, but are not limited to, our effective tax rate for the remainder of 2013, our ability to fund our cash requirements for the foreseeable future with our current assets, long-term investments, cash flow and borrowings under the credit facility, the impact that the inability of the bank providing the credit facility to provide funds thereunder would have on our ability to fund operations, our access to equity and debt financing, and the increase in cash, cash equivalents, and investments in the remainder of 2013. Words such as “expects,” “believes,” “anticipates,” “intends,” “should,” “plans,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product  liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition.

 
1213

 

Quantitative and Qualitative Disclosures About Market Risk

For the quarter ended JuneSeptember 30, 2013, we did not experience any material changes in market risk exposures that affect the quantitative and qualitative disclosures presented in our 2012 Form 10-K.

Item 4.       Controls and Procedures
Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of JuneSeptember 30, 2013. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting for the quarter ended JuneSeptember 30, 2013 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II

OTHER INFORMATION
Item 1.        Legal Proceedings
 
From time to time, we may be involved in claims or litigation that arise in the normal course of business. We are not currently a party to any legal proceedings, which, if decided adversely, would have a material adverse effect on our business, financial condition, or results of operations.

Item 1A.     Risk Factors
 
There were no material changes to the risk factors disclosed in our 2012 Form 10-K.
 
 
1314

 

Item 2.        Unregistered Sales of Equity Securities and Use of Proceeds
 
The table below sets forth information with respect to our purchases of our common stock during each of the three months in the period ended JuneSeptember 30, 2013.

 
 
 
 
 
 
Period
 
 
 
 
Total Number of
Shares
Purchased
 
 
 
 
 
Average Price
Paid per Share
 
 
 
Total Number of Shares Purchased as Part of
Publicly Announced
Plans or Programs
 
Maximum
Number of Shares
that May Yet Be Purchased Under the Plans or Programs (1)
4/1/2013 through 4/30/2013  -   -   -   160,408 
5/1/2013 through 5/31/2013  1,500  $209.01   1,500   158,908 
6/1/2013 through 6/30/2013  7,262  $219.13   7,262   151,646 
Total  8,762  $217.40   8,762   151,646 
 
 
 
 
 
 
Period
 
 
 
 
Total Number of
Shares
Purchased
  
 
 
 
 
Average Price
Paid per Share
  
 
 
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
  
Maximum
Number of
Shares that
May Yet Be
Purchased
Under the Plans
or Programs (1)
 
7/1/2013 through 7/31/2013  -   -    -   151,646 
8/1/2013 through 8/31/2013   -    -    -   151,646 
9/1/2013 through 9/30/2013  4,775  $245.80   4,775   146,871 
Total  4,775  $245.80   4,775   146,871 
 
(1)On August 16, 2011, our Board of Directors approved our current stock repurchase program pursuant to which we can repurchase up to 200,000 shares of our common stock from time to time in open market or privately-negotiated transactions. Our current stock repurchase program has no expiration date but may be terminated by our Board of Directors at any time.



Item 6.        Exhibits

 
Exhibit
Number
Description
 
 
  Number
Description
3.1
Certificate of Incorporation of Atrion Corporation, dated December 30,10, 1996 (1)
        
3.2
Bylaws of Atrion Corporation (as last amended on February 20, 2012)August 14, 2013) (2)
        10.1
Atrion Corporation Short-Term Incentive Compensation Plan
 31.1Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer
   
 31.2Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer
   
 32.1Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes ��� Oxley Act Of 2002
   
 32.2Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
   
 101.INSXBRL Instance Document
   
 101.SCHXBRL Taxonomy Extension Schema Document
   
 101.CALXBRL Taxonomy Extension Calculation Linkbase Document
   
 101.DEFXBRL Taxonomy Extension Definition Linkbase Document
   
 101.LABXBRL Taxonomy Extension Label Linkbase Document
   
 101.PREXBRL Taxonomy Extension Presentation Linkbase Document

Notes
Notes
(1)Incorporated by reference to Appendix B to the Definitive Proxy Statement of Atrion Corporation filed January 10, 1997.
(2)Incorporated by reference to Exhibit 3.1 to the Form 8-K of Atrion Corporation filed February 23, 2012.
(1)           Incorporated by reference to Appendix B to the Definitive Proxy Statement of Atrion Corporation filed January 10, 1997.
(2)           Incorporated by reference to Exhibit 3.1 to the Form 8-K of Atrion Corporation filed August 20, 2013.
 
 
1415

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 Atrion Corporation
 (Registrant)
   
   
Date:  July 31,October 29, 2013By:/s/ David A. Battat                     
  David A. Battat
  President and
  Chief Executive Officer
   
   
   
Date:  July 31,October 29, 2013By:/s/ Jeffery Strickland                  
  Jeffery Strickland
  Vice President and
  Chief Financial Officer
  (Principal Accounting andFinancialand Financial Officer)

 
1516

 


   Exhibit
Exhibit
Number
Description
   
 3.1
Certificate of Incorporation of Atrion Corporation, dated December 30,10, 1996 (1)
   
 3.2
Bylaws of Atrion Corporation (as last amended on February 20, 2012)August 14, 2013) (2)
   
 31.110.1Sarbanes-Oxley Act Section 302 Certification of Chief Executive OfficerAtrion Corporation Short-Term Incentive Compensation Plan
   
 31.2Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer
   
 32.1Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
   
 32.2Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
   
 101.INSXBRL Instance Document
   
 101.SCHXBRL Taxonomy Extension Schema Document
   
 101.CALXBRL Taxonomy Extension Calculation Linkbase Document
   
 101.DEFXBRL Taxonomy Extension Definition Linkbase Document
   
 101.LABXBRL Taxonomy Extension Label Linkbase Document
   
 101.PREXBRL Taxonomy Extension Presentation Linkbase Document

Notes
(1)Incorporated by reference to Appendix B to the Definitive Proxy Statement of Atrion Corporation filed January 10, 1997.
(2)Incorporated by reference to Exhibit 3.1 to the Form 8-K of Atrion Corporation filed February 23, 2012.
 
16(1)           Incorporated by reference to Appendix B to the Definitive Proxy Statement of Atrion Corporation filed January 10, 1997.
(2)           Incorporated by reference to Exhibit 3.1 to the Form 8-K of Atrion Corporation filed August 20, 2013.
17